Gemcitabine Twice Weekly Plus Radiation for Pancreatic Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 1
Volume 9
Issue 1

NEW YORK-A regimen of twice-weekly gemcitabine (Gemzar) plus radiation therapy in patients with unresectable pancreatic cancer appears promising, according to results of a phase I dose escalation study presented at the Chemotherapy Foundation Symposium XVII. The twice-weekly delivery may be more cytotoxic than standard once-weekly dosing, and gemcitabine may act as a radiation sensitizer, said A. William Blackstock, MD, assistant professor of Radiation Oncology, Wake Forest University, Winston-Salem, NC.

NEW YORK—A regimen of twice-weekly gemcitabine (Gemzar) plus radiation therapy in patients with unresectable pancreatic cancer appears promising, according to results of a phase I dose escalation study presented at the Chemotherapy Foundation Symposium XVII. The twice-weekly delivery may be more cytotoxic than standard once-weekly dosing, and gemcitabine may act as a radiation sensitizer, said A. William Blackstock, MD, assistant professor of Radiation Oncology, Wake Forest University, Winston-Salem, NC.

 “Laboratory studies have confirmed that gemcitabine is a potent radiation sensitizer, and ongoing studies of the gemcitabine-radiation interaction are expected to shed more light on the underlying mechanism,” he said.

In this study, Dr. Blackstock and his colleagues escalated gemcitabine from 20 mg/m² to a maximum tolerated dose of 60 mg/m². The agent was given as a 30-minute IV infusion each Monday and Thursday for 5 weeks concurrent with 50.4 Gy of radiation delivered over the course of 5 days. The optimal schedule was to give gemcitabine within 72 hours of delivery of radiation. Dose-limiting toxicities were nausea and vomiting, neutropenia, and thrombocytopenia.

At 40 mg/m², the regimen was well tolerated, although thrombocytopenia frequently necessitated a break in treatment during the third week. Median survival in the 19-patient group was “an encouraging 12.3 months,” Dr. Blackstock said.

Based on these findings, a phase II trial has been initiated through the Cancer and Leukemia Group B (CALGB) to evaluate the efficacy of twice-weekly gemcitabine plus radiation in locally advanced unresectable pancreatic cancer. A second phase II study is looking at the same approach as adjuvant therapy following surgery in resectable pancreatic cancer.

Related Videos
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
An expert from the University of California, Los Angeles suggests that the NALIRIFOX may be a beneficial treatment for patients with pancreatic ductal adenocarcinoma.
Patients with metastatic pancreatic ductal adenocarcinoma who receive NALIRIFOX tend to have more gastrointestinal toxicity while nab-paclitaxel/gemcitabine results in more cytopenias, according to an expert from University of California, Los Angeles.
Related Content